Globally Rising JIA Incidence Drives Growth of Juvenile Idiopathic Arthritis Treatment Market

Global juvenile idiopathic arthritis treatment market was valued at $3.0 billion in 2023 and is growing at a CAGR of 6.1% during the forecast period (2025-2035). Growing emphasis on innovative drug delivery methods, increased clinical trial research in pediatric rheumatology, advancements in biologic and targeted therapeutics, and the rising incidence of JIA globally are all factors driving the market's expansion. In Western countries, JIA was the most common rheumatic condition in children. According to the National Center for Biotechnology Information (NCBI), in January 2023, the incidence and prevalence ranged from 1.6 to 23 new cases per 100,000 children and 3.8 to 400 cases per 100,000 children, respectively, depending on study methodologies, disease categories, and geographic areas. A study carried out in the US and Canada found that there are between 0.041 and 0.061 incidences of JIA for every 1000 children.

Browse the full report description of “Juvenile Idiopathic Arthritis Treatment Market Size, Share & Trends Analysis Report by Type (Systemic JIA (Still’s Disease), Oligoarticular JIA, Polyarticular JIA (Rheumatoid Factor Positive and Negative), Psoriatic Arthritis, Enthesitis-Related Arthritis and Undifferentiated Arthritis), by Route of Administration (Oral, Injectable, and Topical), and by Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Corticosteroids and Other Medications) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/juvenile-idiopathic-arthritis-treatment-market

Advancing Diagnostics and Care for Juvenile Idiopathic Arthritis-

• The increasing number of JIA cases suggests that these areas, especially high-income nations, are in greater need of efficient diagnostic techniques. 
• Regulatory agencies to ensure progress in the targeted regions at enhancing access to healthcare are among the other measures. 
• Enhancing access to a holistic strategy for managing arthritis will help close the gap between high- and low-income areas and improve diagnostic services in even the most neglected areas. 
• The etiology of juvenile idiopathic arthritis is being continuously investigated by clinical trials, that are remarkably expanding the diagnostic landscape. 

Recent Developments

• In June 2024, AbbVie announced that RINVOQ® (upadacitinib) is approved for use in the US in treating children aged two and up who have active psoriatic arthritis (PsA) and polyarticular juvenile idiopathic arthritis (pJIA), as long as they have not responded well to or are intolerant of one or more tumor necrosis factors (TNF) blockers.
• In January 2023, Amgen Inc. announced AMJEVITATM (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is accessible in the US. The US FDA approved AMJEVITA as the first Humira biosimilar. AMJEVITA is a biosimilar to the anti-TNF-? monoclonal antibody Humira®* (adalimumab). An anti-TNF-? monoclonal antibody that shares the same amino acid sequence as Humira is the active component of AMJEVITA. More than 300,000 patients in more than 60 countries have been prescribed AMJEVITA which is marketed outside of the US under the brand name AMGEVITA® (adalimumab).

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Type

o By Route of Administration

o By Drug Class

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Bristol Myers Squibb Co. (BMS), Eli Lilly and Co., Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Pfizer Inc., and others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Juvenile Idiopathic Arthritis Treatment Market Report Segment

By Type

• Systemic JIA (Still’s Disease)
• Oligoarticular JIA
• Polyarticular JIA (Rheumatoid Factor Positive and Negative)
• Psoriatic Arthritis
• Enthesitis-Related Arthritis
• Undifferentiated Arthritis

By Route of Administration

• Oral
• Injectable
• Topical

By Drug Class

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Corticosteroids
• Other Medications (Biologic Agents)

Global Juvenile Idiopathic Arthritis Treatment Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/juvenile-idiopathic-arthritis-treatment-market